Results 31 to 40 of about 419,175 (164)

Cellular senescence impairs the reversibility of pulmonary arterial hypertension

Science Translational Medicine, 2020
The transition from reversible to irreversible pulmonary arterial hypertension involves vascular senescence and can be countered by senolysis. Reversing maladaptive remodeling Pathologic vascular remodeling of pulmonary arterial hypertension (PAH ...
D. E. van der Feen, Guido P. L. Bossers, Q. Hagdorn, J. Moonen, K. Kurakula, R. Szulcek, James Chappell, Francesco Vallania, Michele Donato, K. Kok, J. Kohli, A. Petersen, T. van Leusden, M. Demaria, M. Goumans, R. D. de Boer, P. Khatri, M. Rabinovitch, R. Berger, B. Bartelds   +19 more
semanticscholar   +1 more source

MicroRNAs in pulmonary arterial remodeling [PDF]

, 2013
Pulmonary arterial remodeling is a presently irreversible pathologic hallmark of pulmonary arterial hypertension (PAH). This complex disease involves pathogenic dysregulation of all cell types within the small pulmonary arteries contributing to vascular ...
A Courboulin, A Eulalio, A Ishisaki, A Jelaska, A Kos, A Sacconi, A Tanzer, A Zampetaki, A Zampetaki, AE Frost, AJ Tijsen, AM Walker, Andrew H. Baker, AR Kuhn, AS Flynt, AY Rangrez, AY Yu, B Wojciak-Stothard, BD Adams, BN Davis, BN Davis-Dusenbery, C Atkinson, C Li, C Sweeney, CA Klattenhoff, CD Cool, CL Bockmeyer, D Cifuentes, D Loffler, DB Badesch, DF Liao, DM Patrick, DP Bartel, E Hergenreider, E Mathe, E Rooij Van, ED Michelakis, FE Wang, G Lagna, G Meister, G Simonneau, G Song, GK Owens, H Beppu, H Kang, H Takahashi, H Tazawa, H Valadi, HY Chiang, J Brennecke, J Kim, J Liu, J Niu, J Ryan, J Sarkar, J Skog, J-S Yang, JD Arroyo, Jennifer S. Grant, JH Newman, JM Boucher, JR Thomson, K Abe, K Rakesh, K Wang, KA O’Donnell, KB Lane, KD Taganov, Kevin White, KN Cowan, KR Cordes, KR Stenmark, KR Stenmark, L Elia, L Guo, L He, L He, L Long, L Tu, LA Brennan, LR Frumkin, M Afrakhte, M Brock, M Das, M Deo, M Humbert, M Humbert, M Humbert, M Izikki, M Rabinovitch, M Trabucchi, M Xin, Margaret R. MacLean, MC Chan, MC Chan, MD Moen, MJ Goumans, MM Hoeper, N Liu, N Raver-Shapira, N Volk, NW Morrell, O Platoshyn, P Caruso, P Fasanaro, P Sklepkiewicz, R Kulshreshtha, R Kumarswamy, R Paulin, RD Machado, RJ Dekker, RM O’Connell, S Bonnet, S Chakravarthy, S Jalali, S Mizuno, S Sakamoto, S Sakao, S Yang, SA Moschos, SS Pullamsetti, T Boettger, T Thum, TC Chang, TX Lu, U Bruning, VN Parikh, W Shi, WB Li, X Huang, X Ji, X Long, X Yang, Y Cheng, Y Cheng, Y Ling, Y Liu, YL Jiang   +137 more
core   +2 more sources

The role of endothelin-1 in pulmonary arterial hypertension. [PDF]

, 2014
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core   +1 more source

Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension

Circulation Research, 2020
Supplemental Digital Content is available in the text. Rationale: Right ventricular (RV) fibrosis in pulmonary arterial hypertension contributes to RV failure.
Lian Tian, Danchen Wu, A. Dasgupta, Kuang‐Hueih Chen, J. Mewburn, F. Potus, P. Lima, Z. Hong, Yuan-Yuan Zhao, Charles T. Hindmarch, S. Kutty, S. Provencher, S. Bonnet, G. Sutendra, S. Archer   +14 more
semanticscholar   +1 more source

Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension [PDF]

, 2016
BACKGROUND: Right ventricular (RV) function is a major determinant of exercise intolerance and outcome in idiopathic pulmonary arterial hypertension (IPAH). The aim of the study was to evaluate the incremental prognostic value of echocardiography of the
Badagliacca, Roberto, Fedele, Francesco, Giannetta, E, Manzi, G, Naeije, R, Palange, Paolo, Papa, S, Pezzuto, Beatrice, Poscia, Roberto, Sciomer, S, Valli, G, Vizza, Carmine Dario   +11 more
core   +1 more source

Obesity, estrogens and adipose tissue dysfunction – implications for pulmonary arterial hypertension

Pulmonary Circulation, 2020
Obesity is a prevalent global public health issue characterized by excess body fat. Adipose tissue is now recognized as an important endocrine organ releasing an abundance of bioactive adipokines including, but not limited to, leptin, adiponectin and ...
K. Mair, R. Gaw, M. MacLean
semanticscholar   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J, Balistrieri, Angela, Black, Stephen M, Chen, Jiwang, Desai, Ankit A, Garcia, Joe GN, Gu, Yali, Makino, Ayako, Rischard, Franz, Song, Shanshan, Tang, Haiyang, Vanderpool, Rebecca, Vinjamuri, Sujana, Wang, Jian, Wang, Ziyi, Wu, Kang, Yuan, Jason X-J, Zhang, Qian, Zhou, Guofei   +18 more
core   +1 more source

Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series) [PDF]

, 2016
The proliferative endothelial and smooth muscle cell phenotype, inflammation, and pulmonary vascular remodeling are prominent features of pulmonary arterial hypertension (PAH).
Awad, Keytam S., de Jesus Perez, Vinicio, MacLean, Margaret, West, James D.   +3 more
core   +1 more source

The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension [PDF]

, 2012
Pulmonary arterial hypertension (PAH) is an incurable disorder clinically characterised by a sustained elevation of mean arterial pressure in the absence of systemic involvement.
Machado, Rajiv
core   +2 more sources

MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Angiotensin-converting enzyme 2 (ACE2) converts angiotensin II, a potent vasoconstrictor, to angiotensin-(1–7) and is also a membrane protein that enables coronavirus disease 2019 (COVID ...
Hui Shen, Jiao Zhang, Chen Wang, P. Jain, M. Xiong, Xin Shi, Yuyang Lei, Shanshan Chen, Qian Yin, P. Thistlethwaite, Jian Wang, Kaizheng Gong, Z. Yuan, J. Yuan, J. Shyy   +14 more
semanticscholar   +1 more source